Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

BACKGROUND: Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP). This study evaluated the effects of tofogliflozin on the brachial-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakami, Naoto, Mita, Tomoya, Yoshii, Hidenori, Shiraiwa, Toshihiko, Yasuda, Tetsuyuki, Okada, Yosuke, Torimoto, Keiichi, Umayahara, Yutaka, Kaneto, Hideaki, Osonoi, Takeshi, Yamamoto, Tsunehiko, Kuribayashi, Nobuichi, Maeda, Kazuhisa, Yokoyama, Hiroki, Kosugi, Keisuke, Ohtoshi, Kentaro, Hayashi, Isao, Sumitani, Satoru, Tsugawa, Mamiko, Ryomoto, Kayoko, Taki, Hideki, Nakamura, Tadashi, Kawashima, Satoshi, Sato, Yasunori, Watada, Hirotaka, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784389/
https://www.ncbi.nlm.nih.gov/pubmed/33397376
http://dx.doi.org/10.1186/s12933-020-01206-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784389/
https://www.ncbi.nlm.nih.gov/pubmed/33397376
http://dx.doi.org/10.1186/s12933-020-01206-1

Ejemplares similares